Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental injection aims to boost Chemo's punch in aggressive breast cancer

NCT ID NCT06358573

Recruiting now Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to receive either the injection plus standard treatment or standard treatment alone. The main goal is to see if the combination leads to a higher rate of complete cancer disappearance at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
INT230-6 (a combination of cisplatin, vinblastine, and a cell-penetrating molecule injected into the tumor)
What this could lead to
If successful, this approach could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for people with triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial (61 participants) testing an experimental drug with no marketing approval. The added benefit over standard care is unproven, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TNBC - TRIPLE-NEGATIVE BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni

    RECRUITING

    Bellinzona, 6500, Switzerland

  • HOCH Health Ostschweiz

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Baselland

    RECRUITING

    Liestal, 4410, Switzerland

  • Kantonsspital Graubünden

    RECRUITING

    Chur, 7000, Switzerland

  • Kantonsspital Winterthur

    RECRUITING

    Winterthur, 8401, Switzerland

  • St. Claraspital

    RECRUITING

    Basel, 4058, Switzerland

  • TBZO - Tumor- & Brustzentrum Ostschweiz

    TERMINATED

    Sankt Gallen, 9016, Switzerland

  • Tumor Zentrum Aarau

    TERMINATED

    Aarau, 5000, Switzerland

  • Universitätsspital Zürich - Klinik für Gynäkologie

    RECRUITING

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.